Information  X 
Enter a valid email address

Tissue Regenix Group (TRX)


Wednesday 02 March, 2022

Tissue Regenix Group

Notice of Results

RNS Number : 2533D
Tissue Regenix Group PLC
02 March 2022

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")


Notice of Results

Investor Presentation


Tissue Regenix (AIM: TRX), the regenerative medical devices company, will announce its final results for the year ended 31 December 2021 on Tuesday 15 March 2022.


Investor Briefing

Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will be hosting a live online presentation relating to the final results via the Investor Meet Company platform at 4.30pm on Tuesday 15 March 2022. The presentation is open to all existing and potential shareholders.


Investors can sign up to Investor Meet Company for free and register for the presentation here:  


Investors who already follow Tissue Regenix on the Investor Meet Company platform will be de facto invited.


For more information:


Tissue Regenix Group plc

David Cocke, Chief Financial Officer

Via Walbrook PR



Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Ben Maddison / Alex Price / Nicholas Harland

Tel:  +44(0)20 7710 7600


Walbrook PR Ltd

Alice Woodings / Lianne Cawthorne

Tel: +44 (0)20 7933 8780

 [email protected]



About Tissue Regenix (

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.


In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t